Profound Medical (TSE:PRN) has released an update.
Profound Medical Corp has announced FDA 510(k) clearance for its ‘Contouring Assistant’, an AI software module designed to improve the precision and speed of prostate cancer treatment planning with the TULSA-PRO system. Clinical studies have shown that urologists using the AI module could deliver treatment plans 32% faster with enhanced accuracy. The company continues to innovate in the field of customizable, incision-free therapies and is developing further TULSA-AI modules to optimize treatment outcomes.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.
